We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$71.3B
1-Year Est. Return
56.8%
This Fund
S&P 500
This Quarter
Est. Return
+1.53%
1 Year Est. Return
+56.8%
3 Year Est. Return
+170.28%
5 Year Est. Return
+249.16%
10 Year Est. Return
+1,007.9%
AUM
$64.8B
AUM Growth
-$1.23B
(-1.9%)
Cap. Flow
+$349M
Cap. Flow
% of AUM
0.54%
Top 10 Holdings %
Top 10 Hldgs %
28.4%
Holding
1,116
New
212
Increased
277
Reduced
389
Closed
160
Avg Time Held Equity + Options
13.4
quarters
Top 10 Avg Time Held Equity + Options
20.3
quarters
Top 20 Avg Time Held Equity + Options
21.8
quarters
Avg Time Held Equity only
13.5
quarters
Top 10 Avg Time Held Equity only
20.3
quarters
Top 20 Avg Time Held Equity only
21.8
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$330M |
| 2 |
Coterra Energy
CTRA
|
+$214M |
| 3 |
Boston Scientific
BSX
|
+$204M |
| 4 |
RB Global
RBA
|
+$183M |
| 5 |
Chevron
CVX
|
+$131M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$190M |
| 2 |
Royalty Pharma
RPRX
|
+$187M |
| 3 |
Dover
DOV
|
+$178M |
| 4 |
Boeing
BA
|
+$168M |
| 5 |
Devon Energy
DVN
|
+$155M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.24% |
| 2 | Healthcare | 15.45% |
| 3 | Financials | 12.46% |
| 4 | Industrials | 9.23% |
| 5 | Communication Services | 8.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
NVIDIA
NVDA
$5.54T
| $3.85B | 5.94% |
22,098,810
-159,300
| -0.7% | -$29.2M |
2013 Q2
51 quarters
|
|
2
Apple
AAPL
$4.91T
| $3.31B | 5.11% |
13,046,454
-180,100
| -1% | -$46.9M |
2013 Q2
51 quarters
|
|
3
Microsoft
MSFT
$3.97T
| $2.43B | 3.75% |
6,575,643
-51,500
| -0.8% | -$21.5M |
2013 Q2
51 quarters
|
|
4
Amazon
AMZN
$2.83T
| $1.91B | 2.94% |
9,156,260
+91,500
| +1% | +$20.1M |
2013 Q2
51 quarters
|
|
5
Alphabet (Google) Class A
GOOGL
$4.3T
| $1.5B | 2.31% |
5,215,600
-38,200
| -0.7% | -$12M |
2015 Q4
41 quarters
|
|
6
Broadcom
AVGO
$1.73T
| $1.27B | 1.96% |
4,112,056
-110,000
| -3% | -$36.2M |
2014 Q2
47 quarters
|
|
7
Meta Platforms (Facebook)
META
$1.83T
| $1.18B | 1.82% |
2,059,335
+42,900
| +2% | +$27.5M |
2013 Q4
49 quarters
|
|
8
Alphabet (Google) Class C
GOOG
$4.25T
| $1.18B | 1.82% |
4,104,520
-74,600
| -2% | -$23.4M |
2013 Q2
51 quarters
|
|
9
Tesla
TSLA
$1.51T
| $898M | 1.38% |
2,414,500
-58,300
| -2% | -$24M |
2020 Q4
21 quarters
|
|
10
Eli Lilly
LLY
$1.05T
| $880M | 1.36% |
956,817
+124,525
| +15% | +$126M |
2013 Q2
51 quarters
|
|
11
Berkshire Hathaway Class B
BRK.B
$1.1T
| $804M | 1.24% |
1,677,769
+34,300
| +2% | +$16.8M |
2013 Q2
51 quarters
|
|
12
ConocoPhillips
COP
$161B
| $795M | 1.23% |
6,019,177
-1,018,100
| -14% | -$113M |
2021 Q1
20 quarters
|
|
13
JPMorgan Chase
JPM
$885B
| $710M | 1.1% |
2,415,266
-13,200
| -0.5% | -$4.01M |
2013 Q2
51 quarters
|
|
14
Johnson & Johnson
JNJ
$630B
| $602M | 0.93% |
2,463,008
+252,095
| +11% | +$58.7M |
2013 Q2
51 quarters
|
|
|
15
Revolution Medicines
RVMD
$40.7B
| $533M | 0.82% |
5,475,611
+3,270,056
| +148% | +$330M |
2024 Q1
8 quarters
|
|
|
16
Chevron
CVX
$416B
| $517M | 0.8% |
2,500,766
+720,600
| +40% | +$131M |
2025 Q3
2 quarters
|
|
17
Walmart Inc
WMT
$883B
| $455M | 0.7% |
3,662,026
-211,300
| -5% | -$25.9M |
2013 Q2
51 quarters
|
|
18
Visa
V
$724B
| $450M | 0.69% |
1,489,040
-18,300
| -1% | -$5.88M |
2013 Q2
51 quarters
|
|
19
Procter & Gamble
PG
$351B
| $407M | 0.63% |
2,816,973
-5,247
| -0.2% | -$795K |
2013 Q2
51 quarters
|
|
20
Costco
COST
$420B
| $396M | 0.61% |
397,677
+8,100
| +2% | +$7.89M |
2013 Q2
51 quarters
|
|
21
ExxonMobil
XOM
$695B
| $376M | 0.58% |
2,218,922
-442,800
| -17% | -$64.6M |
2013 Q2
51 quarters
|
|
22
Micron Technology
MU
$1.16T
| $374M | 0.58% |
1,105,603
-5,200
| -0.5% | -$2.04M |
2013 Q2
51 quarters
|
|
|
23
Royalty Pharma
RPRX
$25.3B
| $359M | 0.55% |
7,480,633
-4,259,961
| -36% | -$187M |
2020 Q2
23 quarters
|
|
24
Mastercard
MA
$516B
| $357M | 0.55% |
713,610
-16,950
| -2% | -$8.93M |
2013 Q2
51 quarters
|
|
|
CNTA
25
DELISTED
Centessa Pharmaceuticals
CNTA
| $355M | 0.55% |
8,925,010
-2,356,731
| -21% | -$60.3M |
2023 Q2
11 quarters
|
|
Similar funds
Adage Capital Partners's Q1 2026 Portfolio in Review
As of Q1 2026, Adage Capital Partners held 1,116 positions worth $64.8B, down 1.9% from $66.1B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Adage Capital Partners's Q1 2026 filing shows 212 new, 277 increased, 389 reduced and 160 closed positions. Its largest new stake was Takeda Pharmaceutical: 6,424,984 shares worth $119M. The largest sale was Avidity Biosciences, an estimated $190M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 29% a quarter earlier, followed by Healthcare and Financials.
- Adage Capital Partners's largest Q1 2026 buy was Takeda Pharmaceutical: 6,424,984 shares worth $119M.
- Adage Capital Partners added most to Revolution Medicines in Q1 2026, an estimated $330M increase.
- Adage Capital Partners's biggest Q1 2026 reduction was Royalty Pharma, cutting an estimated $187M.
- Adage Capital Partners fully exited Avidity Biosciences in Q1 2026, selling an estimated $190M.
- Adage Capital Partners's ten largest holdings make up 28% of its $64.8B portfolio in Q1 2026.
- Adage Capital Partners opened 212 new positions and closed 160 in Q1 2026.
- Adage Capital Partners's portfolio value fell 1.9% quarter-over-quarter to $64.8B.
Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.